Skip to main content
Home

Language & Country Selector for Desktop

language-selector-globe Philippines | en

Choose Location

  • Americas
  • Asia Pacific
  • Europe
  • International
  • Middle East & Africa
  • Argentina | es
  • Venezuela | es
  • Brazil | pt
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Mexico | es
  • United States | en
  • Australia | en
  • Bangladesh | en
  • Hong Kong S.A.R. | zh
  • India | en
  • Indonesia | en
  • Japan | ja
  • Korea | ko
  • Mainland China | zh
  • Malaysia | en
  • Pakistan | en
  • Philippines | en
  • Singapore | en
  • Taiwan | zh
  • Austria | de
  • Belgium | fr
  • Bulgaria | bg
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hungary | hu
  • Ireland | en
  • Italy | it
  • Latvia | lv
  • Lithuania | lt
  • Netherlands | nl
  • Norway | no
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Slovakia | sk
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • United Kingdom | en
  • Global | en
  • Sandoz | en
  • Novartis Foundation | en
  • Egypt | en
  • South Africa | en
  • Turkey | tr

Language & Country Selector for Mobile

language-selector-globe Philippines

Choose Location

Americas Asia Pacific Europe International Middle East & Africa
  • Argentina | es
  • Venezuela | es
  • Australia | en
  • Austria | de
  • Bangladesh | en
  • Belgium | fr
  • Brazil | pt
  • Bulgaria | bg
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Egypt | en
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Global | en
  • Greece | el
  • Hong Kong S.A.R. | zh
  • Hungary | hu
  • India | en
  • Indonesia | en
  • Ireland | en
  • Italy | it
  • Japan | ja
  • Korea | ko
  • Latvia | lv
  • Lithuania | lt
  • Mainland China | zh
  • Malaysia | en
  • Mexico | es
  • Netherlands | nl
  • Norway | no
  • Pakistan | en
  • Philippines | en
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Sandoz | en
  • Novartis Foundation | en
  • Serbia | sr
  • Singapore | en
  • Slovakia | sk
  • South Africa | en
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • Taiwan | zh
  • Turkey | tr
  • United Kingdom | en
  • United States | en
    • About 
      • Novartis in Philippines 
      • Strategy 
      • Diversity and Inclusion 
      • People and Culture 
      • Products 
      • Country Leadership Team 
      • Contact 
      Novartis Philippines About About
    • Patients and Caregivers 
      • Novartis Commitment to Patients and Caregivers 
      • Diseases 
      • Patient resources 
      • Products 
      • Adverse Event Reporting 
      Patients and Caregivers Patients and Caregivers
    • Healthcare Professionals 
      • Healthcare professional country resource 
      • Products 
      • Novartis Pipeline 
      • Adverse Event Reporting 
      • Novartis Clinical Trials 
      Healthcare Professionals Healthcare Professionals
    • ESG 
      • Ethical Behavior 
        • Code of Ethics 
        • SpeakUp 
      • Ethics, Risk and Compliance 
      • Access 
      • Environmental Sustainability 
      • Global Health 
      ESG ESG
    • News 
      • News Archive 
      • Stories 
      • Contacts 
      A photo of people in a meeting hall News
    • Careers 
      • Career Search 
      • Meet the teams 
      • Personal Growth 
      • Early Talent 
      • How We Work 
      • Well-being 
      • Diversity and Inclusion 
      • Career Programs 
      • Awards and Recognition 
      Woman wearing a red shirt Careers
    • Coronavirus 
      Coronavirus under the microscope Coronavirus
    Home Novartis Philippines Home
  1. Home
  2. News
  3. News Archive
News Archive Navigation
  • All
  • Media Release
  • Stories
icon
News Archive Navigation Language
  • English
  • French
  • German

January 2023

  • Media ReleaseJan 17, 2023 Achievements and AnnouncementsCareers
    Novartis Healthcare Philippines recognized as a Top Employer for third consecutive year
    Novartis Healthcare Philippines has been officially recognized by the Top Employers Institute as a Top Employer 2023 in the Philippines. To become recognized as a Top Employer, an organization must…
  • Media ReleaseJan 11, 2023 Partnerships and CommitmentsBreast Cancer
    ICanServe, Taguig City, Dashlabs, Novartis launch data-digital project to support breast cancer control program
    The ICanServe Foundation, City of Taguig, local healthcare software startup Dashlabs, and Novartis have launched the Circle of Life Data and Digital Infrastructure project to support the Ating…

November 2022

  • Media ReleaseNov 18, 2022
    Novartis partners with DOH, medical societies, hospitals to strengthen healthcare system and improve heart failure management in PH
    In a developing country like the Philippines, where healthcare delivery is mostly paid through patients' out-of-pocket expenses, the economic burden of heart failure (HF), especially hospitalization…
  • Media ReleaseNov 16, 2022
    Novartis recognized for supporting eye health services amid pandemic
    Novartis Healthcare Philippines was recognized by the National Committee for Sight Preservation (NCSP) for the company’s support to the NCSCP “Maging MATAlino”…

October 2022

  • Media ReleaseOct 24, 2022
    Novartis R&D initiatives help strengthen PH economy, enhance Filipinos' health
    Novartis has made substantial contributions to support the Philippine economy and improve health outcomes of Filipinos. “We are committed to helping strengthen the Philippine economy. In 2021,…

September 2022

  • Media ReleaseSep 30, 2022
    Philippine FDA approves Novartis drug, ribociclib, for advanced breast cancer in males
    The Philippine Food and Drug Administration (FDA) has approved ribociclib for the treatment of metastatic breast cancer. Ribociclib in combination with an aromatase inhibitor or fulvestrant can be…
  • Novartis Philippines launches PIK3CA Testing Program for  Breast Cancer  2.jpeg
    StorySep 23, 2022
    Novartis supports the Southeast Asian Breast Cancer Symposium

August 2022

  • Media ReleaseAug 15, 2022
    Alliance and Partnerships for Patient Innovation and Solutions (APPIS) Initiative announces winners of inaugural Innovator Program
    The APPIS Innovator Program enables patient organizations across Asia Pacific, Middle East and Africa (APMA) to grow and scale existing patient programs. Winners receive financial support, networking…
  • Media ReleaseAug 08, 2022
    Novartis hails Philippine FDA approval of brolucizumab treatment for age-related macular degeneration in time for Sight Saving Month
    The Philippine Food and Drug Administration (FDA) has approved brolucizumab for the treatment of neovascular (wet) age-related macular degeneration (AMD). Wet AMD is the leading cause of severe…

July 2022

  • Media ReleaseJul 27, 2022
    Novartis, Ask Your Derm PH raise awareness on pediatric psoriasis and effective treatments to help children manage symptoms, enjoy life
    Psoriasis causes significant physical, emotional and psychological burden on children and adolescents. Fortunately, effective treatment options are available and parents can take steps to help their…
  • Media ReleaseJul 21, 2022
    Experts encourage women with advanced breast cancer to get tested for PIK3CA mutation to improve treatment outcomes
    Genetic mutations affect breast cancer prognosis, making every patient unique. It is important for patients to get tested to find out the specific mutation, and help doctors develop a personalized…
  • Media ReleaseJul 11, 2022
    Philippine FDA approves Novartis advanced breast cancer treatment, alpelisib
    The Philippine Food and Drug Administration (FDA) has approved alpelisib in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive, human…

Pagination

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • › Next page

Novartis Philippines

Navigate Novartis
  • Patients & Caregivers
  • Healthcare Professionals
  • ESG
  • News
  • Careers
Media Center
  • News Archive
  • Stories
Our Portfolio
  • Novartis Clinical Pipeline
  • Novartis Product Portfolio
Footer Bottom
© 2023 Novartis AG
  • Privacy Policy
  • Terms of Use
  • Cookie Settings
  • Site Map
  • Web Accessibility
Novartis Site Directory
This site is intended for an audience in the Philippines